Amplitude-determined seizure-threshold, electric field modeling, and electroconvulsive therapy antidepressant and cognitive outcomes
Christopher C. Abbott,Jeremy Miller,Danielle Farrar,Miklos Argyelan,Megan Lloyd,Taylor Squillaci,Brian Kimbrell,Sephira Ryman,Thomas R. Jones,Joel Upston,Davin K. Quinn,Angel V. Peterchev,Erik Erhardt,Abhishek Datta,Shawn M. McClintock,Zhi-De Deng
DOI: https://doi.org/10.1038/s41386-023-01780-4
2024-01-13
Neuropsychopharmacology
Abstract:Electroconvulsive therapy (ECT) pulse amplitude, which dictates the induced electric field (E-field) magnitude in the brain, is presently fixed at 800 or 900 milliamperes (mA) without clinical or scientific rationale. We have previously demonstrated that increased E-field strength improves ECT's antidepressant effect but worsens cognitive outcomes. Amplitude-determined seizure titration may reduce the E-field variability relative to fixed amplitude ECT. In this investigation, we assessed the relationships among amplitude-determined seizure-threshold (ST a ), E-field magnitude, and clinical outcomes in older adults (age range 50 to 80 years) with depression. Subjects received brain imaging, depression assessment, and neuropsychological assessment pre-, mid-, and post-ECT. ST a was determined during the first treatment with a Soterix Medical 4×1 High Definition ECT Multi-channel Stimulation Interface (Investigation Device Exemption: G200123). Subsequent treatments were completed with right unilateral electrode placement (RUL) and 800 mA. We calculated E brain defined as the 90th percentile of E-field magnitude in the whole brain for RUL electrode placement. Twenty-nine subjects were included in the final analyses. E brain per unit electrode current, E brain / I , was associated with ST a . ST a was associated with antidepressant outcomes at the mid-ECT assessment and bitemporal electrode placement switch. E brain / I was associated with changes in category fluency with a large effect size. The relationship between ST a and E brain / I extends work from preclinical models and provides a validation step for ECT E-field modeling. ECT with individualized amplitude based on E-field modeling or ST a has the potential to enhance neuroscience-based ECT parameter selection and improve clinical outcomes.
pharmacology & pharmacy,neurosciences,psychiatry